EP3534912A4 - 5-halouracil-modified micrornas and their use in the treatment of cancer - Google Patents
5-halouracil-modified micrornas and their use in the treatment of cancer Download PDFInfo
- Publication number
- EP3534912A4 EP3534912A4 EP17867742.3A EP17867742A EP3534912A4 EP 3534912 A4 EP3534912 A4 EP 3534912A4 EP 17867742 A EP17867742 A EP 17867742A EP 3534912 A4 EP3534912 A4 EP 3534912A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- halouracil
- cancer
- treatment
- modified micrornas
- micrornas
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/335—Modified T or U
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3533—Halogen
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662415740P | 2016-11-01 | 2016-11-01 | |
US201662422298P | 2016-11-15 | 2016-11-15 | |
US201762464491P | 2017-02-28 | 2017-02-28 | |
PCT/US2017/059011 WO2018085198A1 (en) | 2016-11-01 | 2017-10-30 | 5-halouracil-modified micrornas and their use in the treatment of cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3534912A1 EP3534912A1 (en) | 2019-09-11 |
EP3534912A4 true EP3534912A4 (en) | 2020-10-07 |
Family
ID=62077036
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP17867742.3A Pending EP3534912A4 (en) | 2016-11-01 | 2017-10-30 | 5-halouracil-modified micrornas and their use in the treatment of cancer |
EP19878184.1A Pending EP3873613A4 (en) | 2016-11-01 | 2019-10-30 | 5-halouracil-modified micrornas and their use in the treatment of cancer |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19878184.1A Pending EP3873613A4 (en) | 2016-11-01 | 2019-10-30 | 5-halouracil-modified micrornas and their use in the treatment of cancer |
Country Status (12)
Country | Link |
---|---|
US (2) | US11584932B2 (en) |
EP (2) | EP3534912A4 (en) |
JP (2) | JP7130639B2 (en) |
KR (2) | KR102502248B1 (en) |
CN (2) | CN110290794A (en) |
AU (2) | AU2017353907B2 (en) |
BR (1) | BR112019008810A2 (en) |
CA (1) | CA3042401A1 (en) |
IL (1) | IL282836A (en) |
MX (1) | MX2019005101A (en) |
SG (1) | SG11202104571RA (en) |
WO (2) | WO2018085198A1 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112016002709A2 (en) * | 2013-08-08 | 2017-09-12 | Univ New York State Res Found | keratins as biomarkers for cervical cancer and survival |
MX2019005101A (en) * | 2016-11-01 | 2019-08-22 | Univ New York State Res Found | 5-halouracil-modified micrornas and their use in the treatment of cancer. |
US11236337B2 (en) | 2016-11-01 | 2022-02-01 | The Research Foundation For The State University Of New York | 5-halouracil-modified microRNAs and their use in the treatment of cancer |
US10941403B2 (en) | 2018-04-02 | 2021-03-09 | Oregon Health & Science University | Microrna inhibitors as anti-cancer therapeutics |
EP3937980A4 (en) * | 2019-03-14 | 2023-08-02 | The Research Foundation for The State University of New York | Modified micrornas and their use in the treatment of cancer |
CA3175539A1 (en) * | 2020-03-18 | 2021-09-23 | The Research Foundation For The State University Of New York | Modified short-interfering rna compositions and their use in the treatment of cancer |
WO2021262919A2 (en) * | 2020-06-26 | 2021-12-30 | The Research Foundation For The State University Of New York | 5-halouracil-modified micrornas and their use in the treatment of cancer |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012096573A1 (en) * | 2011-01-11 | 2012-07-19 | Interna Technologies B.V. | Mirna for treating diseases and conditions associated with neo-angiogenesis |
WO2013056216A1 (en) * | 2011-10-14 | 2013-04-18 | New York University | Micrornas and methods of using same |
Family Cites Families (147)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5889136A (en) | 1995-06-09 | 1999-03-30 | The Regents Of The University Of Colorado | Orthoester protecting groups in RNA synthesis |
WO2003029459A2 (en) * | 2001-09-28 | 2003-04-10 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Micro-rna molecules |
CA2533701A1 (en) * | 2003-07-31 | 2005-02-17 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding rnas |
US20050261217A1 (en) | 2004-05-18 | 2005-11-24 | Isis Pharmaceuticals Inc. | Modulation of pumilio 1 expression |
US7642348B2 (en) | 2004-10-04 | 2010-01-05 | Rosetta Genomics Ltd | Prostate cancer-related nucleic acids |
US20070259349A1 (en) | 2006-05-04 | 2007-11-08 | Itzhak Bentwich | Bladder cancer-related nucleic acids |
US7825229B2 (en) | 2005-03-25 | 2010-11-02 | Rosetta Genomics Ltd. | Lung cancer-related nucleic acids |
US7592441B2 (en) | 2004-10-04 | 2009-09-22 | Rosetta Genomics Ltd | Liver cancer-related nucleic acids |
EP2322616A1 (en) | 2004-11-12 | 2011-05-18 | Asuragen, Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
JP2008539731A (en) | 2005-05-02 | 2008-11-20 | コールド スプリング ハーバー ラボラトリー | Compositions and methods for diagnosis and treatment of cancer |
US20090209621A1 (en) | 2005-06-03 | 2009-08-20 | The Johns Hopkins University | Compositions and methods for decreasing microrna expression for the treatment of neoplasia |
WO2006128245A1 (en) | 2005-06-03 | 2006-12-07 | Southern Adelaide Health Service-Flinders Medical Centre | Targeting cells with altered microrna expression |
JP5489459B2 (en) | 2005-08-01 | 2014-05-14 | ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション | MicroRNA-based methods and compositions for diagnosis, prognosis and treatment of breast cancer |
EP1937280B1 (en) * | 2005-09-12 | 2014-08-27 | The Ohio State University Research Foundation | Compositions for the therapy of bcl2-associated cancers |
ES2536423T3 (en) | 2006-01-05 | 2015-05-25 | The Ohio State University Research Foundation | MicroRNA based methods for the diagnosis of prostate cancer |
EP2591794A1 (en) | 2006-01-05 | 2013-05-15 | The Ohio State University Research Foundation | MicroRNA expressions abnormalities in pancreatic endocrine and acinar tumors |
ES2429404T3 (en) | 2006-01-05 | 2013-11-14 | The Ohio State University Research Foundation | MicroRNA-based procedures for the diagnosis and prognosis of lung cancer |
EP2522746B1 (en) | 2006-03-02 | 2014-11-12 | The Ohio State University Research Foundation | MicroRNA expression profile associated with pancreatic cancer |
EP1996731A2 (en) | 2006-03-20 | 2008-12-03 | The Ohio State University Research Foundation | Microrna fingerprints during human megakaryocytopoiesis |
SG10201406016SA (en) | 2006-04-03 | 2014-11-27 | Stella Aps | Pharmaceutical composition comprising anti-mirna antisense oligonucleotides |
CA3024953A1 (en) | 2006-04-03 | 2007-10-11 | Roche Innovation Center Copenhagen A/S | Pharmaceutical composition comprising anti-mirna antisense oligonucleotides |
US20080076674A1 (en) | 2006-07-06 | 2008-03-27 | Thomas Litman | Novel oligonucleotide compositions and probe sequences useful for detection and analysis of non coding RNAs associated with cancer |
AU2007272947B2 (en) | 2006-07-13 | 2013-06-06 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Micro-RNA-based methods and compositions for the diagnosis and treatment of colon cancer-related diseases |
US8466117B2 (en) | 2006-07-28 | 2013-06-18 | The Johns Hopkins University | Compositions and methods for modulating angiogenesis |
EP2094848A2 (en) | 2006-09-19 | 2009-09-02 | Asuragen, INC. | Mir-143 regulated genes and pathways as targets for therapeutic intervention |
JP2010504350A (en) | 2006-09-19 | 2010-02-12 | アシュラジェン インコーポレイテッド | Genes and pathways regulated by miR-200 as targets for therapeutic intervention |
US8188255B2 (en) | 2006-10-20 | 2012-05-29 | Exiqon A/S | Human microRNAs associated with cancer |
EP2090665A2 (en) | 2006-10-20 | 2009-08-19 | Exiqon A/S | Novel human microRNAs associated with cancer |
EP3536788A1 (en) | 2006-12-21 | 2019-09-11 | QIAGEN GmbH | Microrna target site blocking oligos and uses thereof |
WO2008074328A2 (en) | 2006-12-21 | 2008-06-26 | Exiqon A/S | Microrna target site blocking oligos and uses thereof |
WO2008092099A2 (en) | 2007-01-26 | 2008-07-31 | Rosetta Genomics, Ltd. | Compositions and methods for treating hematopoietic malignancies |
WO2008095096A2 (en) | 2007-01-31 | 2008-08-07 | Immune Disease Institute | Let-7 microrna and mimetics thereof as therapeutics for cancer |
US9006206B2 (en) | 2007-02-27 | 2015-04-14 | Rosetta Genomics Ltd. | Composition and methods for modulating cell proliferation and cell death |
US8399248B2 (en) | 2007-05-03 | 2013-03-19 | Merck Sharp & Dohme Corp. | Methods of using MIR34 as a biomarker for TP53 functional status |
CA2693031A1 (en) * | 2007-07-18 | 2009-01-22 | The Regents Of The University Colorado | Differential expression of micrornas in nonfailing versus failing human hearts |
JP5401460B2 (en) | 2007-09-06 | 2014-01-29 | ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション | MicroRNA signature in human ovarian cancer |
US8361714B2 (en) * | 2007-09-14 | 2013-01-29 | Asuragen, Inc. | Micrornas differentially expressed in cervical cancer and uses thereof |
EP2190992B1 (en) * | 2007-09-14 | 2013-04-03 | The Ohio State University Research Foundation | Mirna expression in human peripheral blood microvesicles and uses thereof |
US20090136957A1 (en) | 2007-09-15 | 2009-05-28 | Irena Ivanovska | Methods and compositions for regulating cell cycle progression via the miR-106B family |
JP5723156B2 (en) | 2007-10-11 | 2015-05-27 | ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイションThe Ohio State University Research Foundation | Methods and compositions for diagnosis and treatment of esophageal adenocarcinoma |
WO2009058907A2 (en) | 2007-10-29 | 2009-05-07 | Isis Pharmaceuticals, Inc. | Targeting micrornas for the treatment of liver cancer |
WO2009075787A1 (en) | 2007-12-05 | 2009-06-18 | The Johns Hopkins University | Compositions and methods of treating neoplasia |
CN102027129B (en) | 2008-02-28 | 2014-03-12 | 俄亥俄州立大学研究基金会 | Microrna-based methods and compositions for diagnosis, pronosis and treatment of prostate related disorders |
EP2271370A4 (en) | 2008-03-24 | 2011-11-02 | Univ New York | Compositions and methods for diagnosing and treating melanoma |
EP2271757A2 (en) | 2008-03-26 | 2011-01-12 | Asuragen, INC. | Compositions and methods related to mir-16 and therapy of prostate cancer |
US20100113284A1 (en) | 2008-04-04 | 2010-05-06 | Alexander Aristarkhov | Small interfering rna (sirna) target site blocking oligos and uses thereof |
WO2009126726A1 (en) | 2008-04-08 | 2009-10-15 | Asuragen, Inc | Methods and compositions for diagnosing and modulating human papillomavirus (hpv) |
US20110166200A1 (en) | 2008-04-24 | 2011-07-07 | Zhan Zhang | Methods of using mir210 as a biomarker for hypoxia and as a therapeutic agent for treating cancer |
ATE550024T1 (en) | 2008-05-30 | 2012-04-15 | Univ Yale | TARGETED OLIGONUCLEOTIDE COMPOSITIONS FOR MODIFYING GENE EXPRESSION |
US20110071215A1 (en) | 2008-06-02 | 2011-03-24 | Harvey Pass | Compositions and methods for diagnosis, prognosis and treatment of mesothelioma |
EP2300017A4 (en) * | 2008-06-05 | 2012-12-12 | Univ New York State Res Found | Mirnas as therapeutic targets in cancer |
WO2009153774A2 (en) | 2008-06-17 | 2009-12-23 | Rosetta Genomics Ltd. | Compositions and methods for prognosis of ovarian cancer |
EP2310507A4 (en) | 2008-07-08 | 2013-03-20 | David Gladstone Inst | Methods and compositions for modulating angiogenesis |
EP2310021A4 (en) | 2008-07-10 | 2012-06-27 | Merck Sharp & Dohme | Methods of using compositions comprising mir-192 and/or mir-215 for the treatment of cancer |
WO2010023658A2 (en) | 2008-08-28 | 2010-03-04 | Rosetta Genomics Ltd. | Compositions and methods for the treatment of glioblastoma |
JP6128732B2 (en) | 2008-10-03 | 2017-05-17 | クルナ・インコーポレーテッド | Treatment of apolipoprotein-A1 related diseases by suppression of natural antisense transcripts against apolipoprotein-A1 |
WO2010065630A2 (en) | 2008-12-03 | 2010-06-10 | The Johns Hopkins University | Compositions and methods for treating hepatic neoplasia |
MX366774B (en) | 2008-12-04 | 2019-07-24 | Curna Inc | Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirtuin 1. |
ES2637063T3 (en) | 2008-12-04 | 2017-10-10 | Curna, Inc. | Treatment of diseases related to tumor suppressor genes by inhibiting the natural antisense transcript to the gene |
JP5971948B2 (en) | 2008-12-04 | 2016-08-17 | クルナ・インコーポレーテッド | Treatment of vascular endothelial growth factor (VEGF) -related diseases by suppression of natural antisense transcripts against VEGF |
EP2373815A4 (en) | 2008-12-05 | 2012-09-26 | Univ Ohio State Res Found | Microrna-based methods and compositions for the diagnosis and treatment of ovarian cancer |
US20100311815A1 (en) | 2009-02-23 | 2010-12-09 | The Regents Of The University Of Michigan | Mir-101 cancer markers |
CA2753481A1 (en) * | 2009-02-25 | 2010-09-02 | Cepheid | Methods of detecting lung cancer |
EP2403946A4 (en) | 2009-03-04 | 2012-11-14 | Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirt 1 | |
WO2010104796A2 (en) | 2009-03-09 | 2010-09-16 | The J. David Gladstone Institutes | Methods of modulating smooth muscle cell proliferation and differentiation |
US20120087992A1 (en) * | 2009-03-20 | 2012-04-12 | Jingfang Ju | miRNAS AS THERAPEUTIC TARGETS IN CANCER |
US8852940B2 (en) * | 2009-04-01 | 2014-10-07 | The Regents Of The University Of California | Embryonic stem cell specific microRNAs promote induced pluripotency |
AU2010242163B2 (en) * | 2009-04-29 | 2014-10-16 | Academisch Medisch Centrum Bij De Universiteit Van Amsterdam | Means and methods for counteracting, preventing and/or determining heart failure, or a risk of heart failure |
US8318690B2 (en) | 2009-05-01 | 2012-11-27 | Curna, Inc. | Treatment of hemoglobin (HBF/HBG) related diseases by inhibition of natural antisense transcript to HBF/HBG |
ES2609655T3 (en) | 2009-05-06 | 2017-04-21 | Curna, Inc. | Treatment of diseases related to tristetraproline (TTP) by inhibition of natural antisense transcript for TTP |
KR100998365B1 (en) * | 2009-06-29 | 2010-12-06 | 압타바이오 주식회사 | Novel guanosine rich modified oligonucleotides and antiproliferative activity thereof |
WO2011014980A1 (en) | 2009-08-07 | 2011-02-10 | Capitalbio Corporation | Methods and compositions diagnosing cervical cancer and cervical dysplasia, guidding subsequent treatment, determining prognosis, and improving patient survival |
WO2011021177A2 (en) | 2009-08-19 | 2011-02-24 | Rosetta Genomics Ltd. | Compositions and methods for prognosis and treatment of prostate cancer |
WO2011024157A1 (en) | 2009-08-23 | 2011-03-03 | Rosetta Genomics Ltd. | Nucleic acid sequences related to cancer |
WO2011030334A1 (en) | 2009-09-09 | 2011-03-17 | New York University | Compositions and methods for treatment, diagnosis and prognosis of mesothelioma |
CA2780222C (en) * | 2009-11-04 | 2021-11-16 | Diamir, Llc | Methods of using small rna from bodily fluids for diagnosis and monitoring of neurodegenerative diseases |
ES2661813T3 (en) | 2009-12-16 | 2018-04-04 | Curna, Inc. | Treatment of diseases related to membrane transcription factor peptidase, site 1 (mbtps1) by inhibition of the natural antisense transcript to the mbtps1 gene |
JP5982288B2 (en) | 2009-12-29 | 2016-08-31 | カッパーアールエヌエー,インコーポレイテッド | Treatment of tumor protein 63-related diseases by inhibition of natural antisense transcripts against tumor protein 63 (p63) |
DK2521784T3 (en) | 2010-01-04 | 2018-03-12 | Curna Inc | TREATMENT OF INTERFERON REGULATORY FACTOR 8- (IRF8) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPT TO IRF8 |
WO2011088309A1 (en) | 2010-01-14 | 2011-07-21 | Regulus Therapeutics Inc. | Microrna compositions and methods |
ES2671877T3 (en) | 2010-01-25 | 2018-06-11 | Curna, Inc. | Treatment of diseases related to RNASA (H1) by inhibition of the natural antisense transcript to RNASA H1 |
CN102844435B (en) | 2010-02-22 | 2017-05-10 | 库尔纳公司 | Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1 |
WO2011108930A1 (en) * | 2010-03-04 | 2011-09-09 | Interna Technologies Bv | A MiRNA MOLECULE DEFINED BY ITS SOURCE AND ITS DIAGNOSTIC AND THERAPEUTIC USES IN DISEASES OR CONDITIONS ASSOCIATED WITH EMT |
WO2011113030A2 (en) | 2010-03-11 | 2011-09-15 | H.Lee Moffitt Cancer Center & Research Institute | Human cancer micro-rna expression profiles predictive of chemo-response |
WO2011116152A2 (en) | 2010-03-16 | 2011-09-22 | Sanford -Burnham Medical Research Institute | Delivery of agents using interfering nanoparticles |
EP2556160A4 (en) | 2010-04-09 | 2013-08-21 | Curna Inc | Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21 |
WO2011128886A1 (en) | 2010-04-12 | 2011-10-20 | Ramot At Tel Aviv University Ltd. | A micro-rna for cancer diagnosis, prognosis and therapy |
TWI586356B (en) | 2010-05-14 | 2017-06-11 | 可娜公司 | Treatment of par4 related diseases by inhibition of natural antisense transcript to par4 |
AR081209A1 (en) | 2010-05-19 | 2012-07-04 | Opko Curna Llc | TREATMENT OF DISEASES RELATED TO PROTEIN 11 OF TYPE LYMPHOMA 2 OF CELLS B, (BCL2, BCL2L11) BY INHIBITION OF THE NATURAL ANTISENTIDE TRANSCRIPT TO BCL2L11 |
KR20180053419A (en) | 2010-05-26 | 2018-05-21 | 큐알엔에이, 인크. | Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1 |
WO2011157294A1 (en) | 2010-06-16 | 2011-12-22 | Universita' Degli Studi Di Padova | Compositions for use in treating or preventing cancer, breast cancer, lung cancer, ovarian cancer, metastasis, heart failure, cardiac remodelling, dilated cardiomyopathy, autoimmune diseases, or diseases or disorders related thereto |
WO2012009347A2 (en) | 2010-07-12 | 2012-01-19 | Opko Curna Llc | Treatment of bcl2 binding component 3 (bbc3) related diseases by inhibition of natural antisense transcript to bbc3 |
US9333218B2 (en) * | 2010-07-15 | 2016-05-10 | Emory University | MicroRNA compositions and methods related thereto |
CN103180461A (en) | 2010-07-25 | 2013-06-26 | 纽约大学 | Compositions and methods for prognosis of mesothelioma |
EP2957642A3 (en) | 2010-08-01 | 2016-03-30 | Tel HaShomer Medical Research Infrastructure and Services Ltd. | Microrna patterns for the diagnosis, prognosis and treatment of melanoma |
CA2813901C (en) | 2010-10-06 | 2019-11-12 | Curna, Inc. | Treatment of sialidase 4 (neu4) related diseases by inhibition of natural antisense transcript to neu4 |
KR101343616B1 (en) | 2010-10-08 | 2013-12-20 | 연세대학교 산학협력단 | Pharmaceutical Compositions for Treating Pancreatic Cancer and Screening Method for Pancreatic Cancer Therapeutic Agent |
EP2638163B1 (en) | 2010-11-12 | 2017-05-17 | The General Hospital Corporation | Polycomb-associated non-coding rnas |
CA2821952A1 (en) | 2010-12-15 | 2012-06-21 | Medimmune, Llc | Melanoma treatments |
AR093183A1 (en) * | 2010-12-31 | 2015-05-27 | Anthrogenesis Corp | INCREASE IN THE POWER OF PLACENTA MOTHER CELLS USING MODULATING RNA MOLECULES |
WO2012093384A1 (en) | 2011-01-03 | 2012-07-12 | Rosetta Genomics Ltd. | Compositions and methods for treatment of ovarian cancer |
AU2012212105A1 (en) * | 2011-02-03 | 2013-09-12 | Mirna Therapeutics, Inc. | Synthetic mimics of miR-124 |
US9132152B2 (en) | 2011-02-10 | 2015-09-15 | The Regents Of The University Of California | Compositions and methods for generating induced pluripotent stem cells |
EP2686448A4 (en) | 2011-03-18 | 2015-08-05 | Baylor Res Inst | Changes in the expression of mir-200c/141 cluster of micrornas as biomarkers for epithelial-to-mesenchymal transition in human colorectal cancer metastasis |
US8987224B2 (en) * | 2011-08-05 | 2015-03-24 | Baylor College Of Medicine | MicroRNA-198 as a tumor suppressor in pancreatic cancer |
US9745578B2 (en) | 2011-11-30 | 2017-08-29 | Cedars-Sinai Medical Center | Targeting microRNA miR-409-3P to treat prostate cancer |
WO2013082499A1 (en) | 2011-11-30 | 2013-06-06 | Cedars-Sinai Medical Center | Targeting micrornas mir-409-5p, mir-379 and mir-154* to treat prostate cancer bone metastasis and drug resistant lung cancer |
US20140363469A1 (en) * | 2012-01-19 | 2014-12-11 | Alnylam Pharmaceuticals, Inc. | Viral attenuation and vaccine production |
US20150031750A1 (en) | 2012-03-15 | 2015-01-29 | The Scripps Research Institute | Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf |
US20150211004A1 (en) * | 2012-04-20 | 2015-07-30 | Agency For Science, Technology And Research | Rnai-based therapies for cardiomyopathies, muscular dystrophies and laminopathies |
US20150159161A1 (en) | 2012-05-16 | 2015-06-11 | Rana Therapeutics, Inc. | Compositions and methods for modulating pten expression |
US10059941B2 (en) | 2012-05-16 | 2018-08-28 | Translate Bio Ma, Inc. | Compositions and methods for modulating SMN gene family expression |
CN104602714A (en) | 2012-05-16 | 2015-05-06 | Rana医疗有限公司 | Compositions and methods for modulating bdnf expression |
CN104582737A (en) | 2012-05-16 | 2015-04-29 | Rana医疗有限公司 | Compositions and methods for modulating APOA1 and ABCA1 expression |
JP2015518712A (en) | 2012-05-16 | 2015-07-06 | ラナ セラピューティクス インコーポレイテッド | Compositions and methods for modulating MECP2 expression |
EA201492120A1 (en) | 2012-05-16 | 2015-10-30 | Рана Терапьютикс, Инк. | COMPOSITIONS AND METHODS FOR MODULATING ATP2A2 EXPRESSION |
AP2014008100A0 (en) | 2012-05-16 | 2014-12-31 | Gen Hospital Corp | Compositions and methods for modulating hemoglobingene family expression |
AU2013262656A1 (en) | 2012-05-16 | 2015-01-22 | Rana Therapeutics, Inc. | Compositions and methods for modulating UTRN expression |
CA2873809A1 (en) | 2012-05-16 | 2013-11-21 | Rana Therapeutics, Inc. | Compositions and methods for modulating gene expression |
US9758785B2 (en) | 2012-07-12 | 2017-09-12 | Baylor College Of Medicine | miR-520 microRNAs sensitize cancers to platinum-based therapy |
US9096853B2 (en) * | 2012-09-24 | 2015-08-04 | U.S. Department Of Veterans Affairs | Modified siRNA molecules incorporating 5-fluoro-2′-deoxyuridine residues to enhance cytotoxicity |
CN114177166A (en) | 2012-10-31 | 2022-03-15 | 洛克菲勒大学 | Treatment and diagnosis of colon cancer |
WO2014072357A1 (en) | 2012-11-06 | 2014-05-15 | Interna Technologies B.V. | Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated b-raf pathway |
US9416369B2 (en) * | 2012-12-18 | 2016-08-16 | University Of Washington Through Its Center For Commercialization | Methods and compositions to modulate RNA processing |
US10697020B2 (en) * | 2013-05-15 | 2020-06-30 | The Research Foundation For The State University Of New York | MicroRNA-129 as a biomarker for colorectal cancer |
EP3004354A4 (en) | 2013-06-07 | 2017-01-11 | Rana Therapeutics, Inc. | Compositions and methods for modulating foxp3 expression |
WO2014201417A1 (en) * | 2013-06-14 | 2014-12-18 | The University Of Kansas | Methods and compositions of modulating tumor initiating cells and the use thereof |
WO2015066034A1 (en) * | 2013-10-28 | 2015-05-07 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for modulating neuronal excitability and motor behavior |
US20160312301A1 (en) | 2013-12-20 | 2016-10-27 | The Feinstein Institute For Medical Research | Microrna biomarkers for ovarian cancer |
EP3105327A4 (en) | 2014-02-12 | 2017-10-18 | Thomas Jefferson University | Compositions and methods of using microrna inhibitors |
KR101596166B1 (en) | 2014-10-07 | 2016-02-19 | 가톨릭대학교 산학협력단 | A Use of microRNA for Ddiagnosing and Treating Brest Cancer |
US10900036B2 (en) | 2015-03-17 | 2021-01-26 | The General Hospital Corporation | RNA interactome of polycomb repressive complex 1 (PRC1) |
US20180221393A1 (en) | 2015-08-03 | 2018-08-09 | Biokine Therapeutics Ltd. | Cxcr4 binding agents for treatment of diseases |
US10053696B2 (en) | 2016-01-21 | 2018-08-21 | University Of South Carolina | MiRNA-489 in treatment of breast cancer |
MX2019005101A (en) | 2016-11-01 | 2019-08-22 | Univ New York State Res Found | 5-halouracil-modified micrornas and their use in the treatment of cancer. |
US11236337B2 (en) | 2016-11-01 | 2022-02-01 | The Research Foundation For The State University Of New York | 5-halouracil-modified microRNAs and their use in the treatment of cancer |
US10443055B2 (en) | 2016-12-22 | 2019-10-15 | Beth Israel Deaconess Medical Center | Compounds that target MYC microRNA responsive elements for the treatment of MYC-associated cancer |
WO2018129402A1 (en) | 2017-01-06 | 2018-07-12 | Oregon Health & Science University | Compositions and methods used in diagnosing and treating colorectal cancer |
US10314855B2 (en) | 2017-01-23 | 2019-06-11 | Trustees Of Boston University | Methods relating to lung cancer |
KR101953300B1 (en) | 2018-06-22 | 2019-02-28 | 의료법인 성광의료재단 | A composition, kit and method for diagnosing and treating taxane-based anticancer drugs resistance cancer |
WO2020061397A1 (en) | 2018-09-20 | 2020-03-26 | Modernatx, Inc. | Compositions and methods for delivery of nucleic acids |
KR20210091732A (en) | 2018-11-13 | 2021-07-22 | 레굴루스 테라퓨틱스 인크 | MicroRNAs and methods to modulate MIR-10B activity |
WO2020154207A1 (en) | 2019-01-22 | 2020-07-30 | Research Institute At Nationwide Children's Hospital | A novel method for monitoring and treating oral cancer |
EP3937980A4 (en) | 2019-03-14 | 2023-08-02 | The Research Foundation for The State University of New York | Modified micrornas and their use in the treatment of cancer |
US20220275374A1 (en) | 2019-11-14 | 2022-09-01 | The Board Of Regents Of The University Of Oklahoma | Oligonucleotide interference treatments of prostate cancer |
US11965162B2 (en) | 2020-04-16 | 2024-04-23 | The Johns Hopkins University | MicroRNA and inhibitors thereof and methods of treatment |
WO2021262919A2 (en) | 2020-06-26 | 2021-12-30 | The Research Foundation For The State University Of New York | 5-halouracil-modified micrornas and their use in the treatment of cancer |
-
2017
- 2017-10-30 MX MX2019005101A patent/MX2019005101A/en unknown
- 2017-10-30 BR BR112019008810A patent/BR112019008810A2/en active Search and Examination
- 2017-10-30 AU AU2017353907A patent/AU2017353907B2/en active Active
- 2017-10-30 CA CA3042401A patent/CA3042401A1/en active Pending
- 2017-10-30 WO PCT/US2017/059011 patent/WO2018085198A1/en unknown
- 2017-10-30 EP EP17867742.3A patent/EP3534912A4/en active Pending
- 2017-10-30 JP JP2019523008A patent/JP7130639B2/en active Active
- 2017-10-30 KR KR1020197015788A patent/KR102502248B1/en active IP Right Grant
- 2017-10-30 CN CN201780081456.7A patent/CN110290794A/en active Pending
-
2018
- 2018-10-31 US US16/176,137 patent/US11584932B2/en active Active
-
2019
- 2019-10-30 CN CN201980087509.5A patent/CN113573781A/en active Pending
- 2019-10-30 KR KR1020217016590A patent/KR20210088614A/en active Search and Examination
- 2019-10-30 WO PCT/US2019/058706 patent/WO2020092466A1/en unknown
- 2019-10-30 SG SG11202104571RA patent/SG11202104571RA/en unknown
- 2019-10-30 AU AU2019371830A patent/AU2019371830A1/en active Pending
- 2019-10-30 EP EP19878184.1A patent/EP3873613A4/en active Pending
-
2021
- 2021-05-02 IL IL282836A patent/IL282836A/en unknown
-
2022
- 2022-08-24 JP JP2022133279A patent/JP2022173194A/en active Pending
-
2023
- 2023-01-25 US US18/159,233 patent/US20230365972A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012096573A1 (en) * | 2011-01-11 | 2012-07-19 | Interna Technologies B.V. | Mirna for treating diseases and conditions associated with neo-angiogenesis |
WO2013056216A1 (en) * | 2011-10-14 | 2013-04-18 | New York University | Micrornas and methods of using same |
Non-Patent Citations (5)
Title |
---|
FESLER ET AL.: "Abstract 4403: Development of 5-FU modified tumor suppressor miRNAs as a platform for miRNA based cancer therapeutics | Cancer Research", 1 July 2018 (2018-07-01), XP055685588, Retrieved from the Internet <URL:https://cancerres.aacrjournals.org/content/78/13_Supplement/4403> [retrieved on 20200415] * |
JENNY K W LAM ET AL: "siRNA Versus miRNA as Therapeutics for Gene Silencing", MOLECULAR THERAPY-NUCLEIC ACIDS, vol. 4, 1 January 2015 (2015-01-01), US, pages 1 - 20, XP055380675, ISSN: 2162-2531, DOI: 10.1038/mtna.2015.23 * |
S.-Y. WU ET AL: "Development of modified siRNA molecules incorporating 5-fluoro-2'-deoxyuridine residues to enhance cytotoxicity", NUCLEIC ACIDS RESEARCH, vol. 41, no. 8, 1 April 2013 (2013-04-01), pages 4650 - 4659, XP055685599, ISSN: 0305-1048, DOI: 10.1093/nar/gkt120 * |
VA-LIN CHIU AND TARIQ M RANA: "siRNA function in RNAi: A chemical modification analysis", RNA, COLD SPRING HARBOR LABORATORY PRESS, US, vol. 9, no. 9, 1 January 2003 (2003-01-01), pages 1034 - 1048, XP008158876, ISSN: 1355-8382, DOI: 10.1261/RNA.5103703 * |
WATTS J K ET AL: "Chemically modified siRNA: tools and applications", DRUG DISCOVERY TODAY, ELSEVIER, AMSTERDAM, NL, vol. 13, no. 19/20, 1 October 2008 (2008-10-01), pages 842 - 855, XP002558509, ISSN: 1359-6446, [retrieved on 20080707], DOI: 10.1016/J.DRUDIS.2008.05.007 * |
Also Published As
Publication number | Publication date |
---|---|
KR20210088614A (en) | 2021-07-14 |
SG11202104571RA (en) | 2021-06-29 |
KR20190086688A (en) | 2019-07-23 |
AU2017353907B2 (en) | 2023-11-30 |
JP7130639B2 (en) | 2022-09-05 |
EP3534912A1 (en) | 2019-09-11 |
MX2019005101A (en) | 2019-08-22 |
AU2019371830A1 (en) | 2021-06-03 |
CN113573781A (en) | 2021-10-29 |
CN110290794A (en) | 2019-09-27 |
IL282836A (en) | 2021-06-30 |
EP3873613A4 (en) | 2023-11-15 |
WO2018085198A1 (en) | 2018-05-11 |
JP2022173194A (en) | 2022-11-18 |
US20190062754A1 (en) | 2019-02-28 |
CA3042401A1 (en) | 2018-05-11 |
AU2017353907A1 (en) | 2019-05-23 |
KR102502248B1 (en) | 2023-02-21 |
JP2019533697A (en) | 2019-11-21 |
US20230365972A1 (en) | 2023-11-16 |
BR112019008810A2 (en) | 2019-07-16 |
US11584932B2 (en) | 2023-02-21 |
WO2020092466A1 (en) | 2020-05-07 |
EP3873613A1 (en) | 2021-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201904695B (en) | Amino-triazolopyridine compounds and their use in treating cancer | |
EP3325473A4 (en) | Compounds and uses thereof in the treatment of cancers and other medical conditions | |
HK1256283A1 (en) | Dihydroimidazopyrazinone derivatives useful in the treatment of cancer | |
EP3873613A4 (en) | 5-halouracil-modified micrornas and their use in the treatment of cancer | |
IL276733A (en) | Use of eribulin in the treatment of cancer | |
ZA201904966B (en) | Hydrocarbylsulfonyl-substituted pyridines and their use in the treatment of cancer | |
EP3151829A4 (en) | Novel sesquiterpene derivatives and their use in inflammation and cancer treatment | |
EP3236992A4 (en) | Peptides and their use in the treatment of skin | |
GB201514021D0 (en) | Novel Pyridines and their use in the treatment of cancer | |
ZA201904967B (en) | Heteroarylsulfonyl-substituted pyridines and their use in the treatment of cancer | |
EP3222721A4 (en) | Novel precursor mirna and application thereof in tumor treatment | |
IL286334A (en) | Modified micrornas and their use in the treatment of cancer | |
EP3411122A4 (en) | Cancer vaccines and methods of treatment using the same | |
IL261648A (en) | Cinnolin-4-amine compounds and their use in treating cancer | |
EP3337784A4 (en) | Use of ureidomustine (bo-1055) in cancer treatment | |
PT3258931T (en) | Use of cabazitaxel in the treatment of prostate cancer | |
EP3126521A4 (en) | Hnf4g-rspo2 fusion gene and use thereof in treatment of cancer | |
EP3380468B8 (en) | Bis-pyridazine compounds and their use in treating cancer | |
EP3380112A4 (en) | Peptides and their use in the treatment of hair | |
IL269121A (en) | Usl-311 for use in the treatment of cancer | |
GB201514015D0 (en) | Novel pyridazinones and their use in the treatment of cancer | |
GB201514018D0 (en) | Novel tricyclic compounds and their use in the treatment of cancer | |
AU2017902291A0 (en) | Antibody-Drug-Conjugates And Uses Thereof For The Treatment of Cancer | |
AU2016905362A0 (en) | Compounds and use thereof in methods of treatment | |
GB201403086D0 (en) | Selection of virus and agent useful in the treatment of cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20190531 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C12N 15/113 20100101AFI20200525BHEP Ipc: A61K 31/7115 20060101ALI20200525BHEP Ipc: A61K 48/00 20060101ALI20200525BHEP Ipc: A61P 35/00 20060101ALI20200525BHEP |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40013929 Country of ref document: HK |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: A61K0031710500 Ipc: C12N0015113000 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20200903 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/7115 20060101ALI20200828BHEP Ipc: C12N 15/113 20100101AFI20200828BHEP Ipc: A61P 35/00 20060101ALI20200828BHEP Ipc: A61K 48/00 20060101ALI20200828BHEP |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230528 |